Obecabtagene autoleucel
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphocytic Leukemia (ALL)
Conditions
Acute Lymphocytic Leukemia (ALL)
Trial Timeline
Aug 26, 2025 → May 31, 2030
NCT ID
NCT07053059About Obecabtagene autoleucel
Obecabtagene autoleucel is a phase 2 stage product being developed by Autolus Therapeutics for Acute Lymphocytic Leukemia (ALL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07053059. Target conditions include Acute Lymphocytic Leukemia (ALL).
What happened to similar drugs?
20 of 20 similar drugs in Acute Lymphocytic Leukemia (ALL) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07400029 | Phase 2 | Recruiting |
| NCT07053800 | Phase 2 | Recruiting |
| NCT07053059 | Phase 2 | Recruiting |
Competing Products
20 competing products in Acute Lymphocytic Leukemia (ALL)